Follow the people · Insider
David J. Wambeke
David J. Wambeke files insider transactions with the SEC as a chief business officer of Neuroone Medical Technologies (NMTC). We hold 2 disclosed purchases and sales filed since 11 April 2023, 1 of them in the last 90 days.
- Files forNMTC
- Disclosed buys and sells2 in all, 1 in the last 90 days
- Last disclosure8 September 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 1 March 2026 — 28 August 2026Chief Business Officer · Neuroone Medical Technologies (NMTC)6 Form 4 lines · source: SEC Form 4
- Filed 10 April 2023 — 1 June 2025Chief Business Officer · DiaMedica Therapeutics (DMAC)6 Form 4 lines · source: SEC Form 4
Everything they disclosed
12 entries, newest first — one per disclosure report, one per Form 4 line- ▲ bought on the open market 33,333 shares of Neuroone Medical TechnologiesSEC Form 48 September 2026Common Stock · traded 27 August 2026 · filed 8 September 2026
- was granted 35,000 shares of Neuroone Medical Technologies (a derivative holding)SEC Form 48 September 2026Option to Purchase Common Stock · traded 28 August 2026 · filed 8 September 2026
- ▲ bought on the open market 1,000,000 shares of Neuroone Medical TechnologiesSEC Form 43 March 2026Common Stock · traded 1 March 2026 · filed 3 March 2026
- was granted 500,000 shares of Neuroone Medical Technologies (a derivative holding)SEC Form 43 March 2026Option to Purchase Common Stock · traded 1 March 2026 · filed 3 March 2026
- was granted 500,000 shares of Neuroone Medical Technologies (a derivative holding)SEC Form 43 March 2026Option to Purchase Common Stock · traded 1 March 2026 · filed 3 March 2026
- ▲ bought on the open market 1,000,000 shares of Neuroone Medical TechnologiesSEC Form 43 March 2026Common Stock · traded 1 March 2026 · filed 3 March 2026
- was granted 250,000 shares of DiaMedica Therapeutics (a derivative holding)SEC Form 43 June 2025Stock Option (right to buy) · traded 1 June 2025 · filed 3 June 2025
- was granted 130,000 shares of DiaMedica Therapeutics (a derivative holding)SEC Form 43 June 2024Stock Option (right to buy) · traded 1 June 2024 · filed 3 June 2024
- ▲ bought on the open market 20,000 shares of DiaMedica TherapeuticsSEC Form 416 November 2023Voting Common Shares, no par value per share · traded 16 November 2023 · filed 16 November 2023
- ▲ bought on the open market 38,364 shares of DiaMedica TherapeuticsSEC Form 426 June 2023Voting Common Shares, no par value per share · traded 23 June 2023 · filed 26 June 2023
- was granted 140,000 shares of DiaMedica Therapeutics (a derivative holding)SEC Form 411 April 2023Stock Option (right to buy) · traded 10 April 2023 · filed 11 April 2023
- ▲ bought on the open market 468,750 shares of DiaMedica TherapeuticsSEC Form 411 April 2023Voting Common Shares, no par value per share · traded 10 April 2023 · filed 11 April 2023
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.